Voluntary Faculty
Voluntary faculty are typically clinicians or others who are employed outside of the School but make significant contributions to department programs at the medical center or at affiliate institutions.
Voluntary rank detailsMona Shahriari, MD
Associate Clinical ProfessorDownloadHi-Res Photo
About
Copy Link
Appointments
Dermatology
Associate Clinical ProfessorPrimary
Other Departments & Organizations
Education & Training
- MD
- University of Connecticut School of Medicine, (2011)
Research
Copy Link
Research at a Glance
Yale Co-Authors
Frequent collaborators of Mona Shahriari's published research.
Christopher Bunick, MD, PhD
Bruce Strober, MD, PhD, FAAD
Publications
2025
LB1122 Burden of atopic dermatitis in the United States: National and state-level trends (2010–2021)
Akbarialiabad H, Shahriari M, Bunick C, Grada A. LB1122 Burden of atopic dermatitis in the United States: National and state-level trends (2010–2021). Journal Of Investigative Dermatology 2025, 145: s195. DOI: 10.1016/j.jid.2025.06.1395.Peer-Reviewed Original ResearchTralokinumab as a Therapeutic Alternative for Dupilumab-associated Arthralgia in Atopic Dermatitis: A Multi-center Case Series.
Greenberg A, Shahriari M, Cameron M, Payette M, Dasilva D, Damiani G, Herman E, Eminger L, Issa N, Rodriguez A, Del Rosso J, Kang Y, Cohen J, Bunick C. Tralokinumab as a Therapeutic Alternative for Dupilumab-associated Arthralgia in Atopic Dermatitis: A Multi-center Case Series. The Journal Of Clinical And Aesthetic Dermatology 2025, 18: 16-19. PMID: 40538523, PMCID: PMC12175839.Peer-Reviewed Original ResearchCitationsConceptsInvestigator's Global AssessmentAdverse eventsFood and Drug AdministrationAtopic dermatitisInterleukin-4Alternative therapiesSwitching to alternative therapiesSurface area of involvementDiscontinuation of dupilumabDiscontinuation of treatmentT cell populationsChronic inflammatory skin conditionMulti-center case seriesUnited States Food and Drug AdministrationStates Food and Drug AdministrationBody surface areaOptimal clinical outcomesInflammatory skin conditionAD signsTargeting interleukins 4Area of involvementSystemic treatmentT cellsCase seriesClinical outcomes
2024
Atopic dermatitis in women: special considerations in the childbearing years
Valentini R, Shahriari M. Atopic dermatitis in women: special considerations in the childbearing years. International Journal Of Women's Dermatology 2024, 10: e151. PMID: 38860232, PMCID: PMC11164005, DOI: 10.1097/jw9.0000000000000151.Peer-Reviewed Original ResearchCitationsAltmetricConceptsWomen of Childbearing AgeAtopic dermatitisChildbearing ageTreating women of childbearing ageReview special considerationsRandomized Controlled TrialsSystemic therapyTopical therapyGoogle Scholar databasesRecommended therapyInflammatory dermatosesUncontrolled ADLactating womenTreated womenPotential therapiesChildbearing yearsTherapyControlled TrialsGold standardQuality of lifeUnborn babyDatabase inceptionRelevant articlesOptimal careOptimal outcomesUpadacitinib for the treatment of psoriasiform and spongiotic dermatitis: A multicenter case series
Shahriari N, Strober B, Shahriari M. Upadacitinib for the treatment of psoriasiform and spongiotic dermatitis: A multicenter case series. JAAD Case Reports 2024, 49: 106-109. PMID: 38952860, PMCID: PMC11214991, DOI: 10.1016/j.jdcr.2024.05.009.Peer-Reviewed Original ResearchCitationsLebrikizumab Provides Rapid Clinical Responses Across All Eczema Area and Severity Index Body Regions and Clinical Signs in Adolescents and Adults with Moderate-to-Severe Atopic Dermatitis
Simpson E, de Bruin-Weller M, Hong H, Staumont-Sallé D, Blauvelt A, Eyerich K, Gooderham M, Shahriari M, Mallbris L, Atwater A, Rueda M, Ding Y, Liu Z, Agell H, Silverberg J. Lebrikizumab Provides Rapid Clinical Responses Across All Eczema Area and Severity Index Body Regions and Clinical Signs in Adolescents and Adults with Moderate-to-Severe Atopic Dermatitis. Dermatology And Therapy 2024, 14: 1145-1160. PMID: 38700646, PMCID: PMC11116327, DOI: 10.1007/s13555-024-01158-4.Peer-Reviewed Original ResearchCitationsAltmetricConceptsEczema Area and Severity IndexWeek 2Clinical signsHead and neck regionRefractory to treatmentBody regionsSeverity of ADClinical responseEczema AreaEfficacy measuresPlaceboAtopic dermatitisLebrikizumabNeck regionIntroductionAtopic dermatitisMonotherapyWeeksPost-hocErythemaPatientsSeveritySeverity IndexEczemaDermatitisLichenification533 - Long-term 5-year safety of upadacitinib in moderate-to-severe atopic dermatitis: an integrated analysis including over 7000 patient-years of exposure
Bunick C, Chovatiya R, Guttman E, Shahriari M, Boguniewicz M, Gao X, Greiwe J, Blauvelt A, Schuttelaar M, Irvine A, Levy G, Platt A, Dilley D, Teixeira H, Altman K, Grada A, Silverberg J. 533 - Long-term 5-year safety of upadacitinib in moderate-to-severe atopic dermatitis: an integrated analysis including over 7000 patient-years of exposure. British Journal Of Dermatology 2024, 190: ii35-ii36. DOI: 10.1093/bjd/ljad498.037.Peer-Reviewed Original ResearchCitationsConceptsNon-melanoma skin cancerMajor adverse cardiovascular eventsVenous thromboembolic eventsAtopic dermatitisAdverse eventsAdjudicated major adverse cardiovascular eventsOral Janus kinase 1Rate of serious infectionTreatment-emergent adverse eventsLong-term safety dataDuration of follow-upConcomitant topical corticosteroidsEfficacy of upadacitinibDouble-blind periodRate of adverse eventsPhase 3 studyDoses of upadacitinibEczematous skin lesionsExposure-adjusted ratesMATERIALS & METHODSYear of treatmentAdverse cardiovascular eventsBenefit-risk profileInflammatory skin diseaseLong-term safetyA retrospective multicenter case series of real-world tralokinumab use in dupilumab-experienced patients
Herman E, Burgy J, Shahriari M. A retrospective multicenter case series of real-world tralokinumab use in dupilumab-experienced patients. JAAD Case Reports 2024, 46: 40-44. PMID: 38510837, PMCID: PMC10950487, DOI: 10.1016/j.jdcr.2024.01.021.Peer-Reviewed Original ResearchCitationsReal-World Tralokinumab Use in Dupilumab-Experienced Patients: A Eetrospective Multi-Center Case Series
Herman E, Burgy J, Shahriari M. Real-World Tralokinumab Use in Dupilumab-Experienced Patients: A Eetrospective Multi-Center Case Series. SKIN The Journal Of Cutaneous Medicine 2024, 8: s321. DOI: 10.25251/skin.8.supp.321.Peer-Reviewed Original ResearchConceptsTreated with dupilumabAtopic dermatitisDupilumab treatmentTralokinumab treatmentCase seriesSafety profileLong-term disease controlHead-to-head studiesDiscontinued dupilumab treatmentTreated with topicalMulti-center case seriesDuration of treatmentLack of efficacyEvaluate clinical findingsBiologic dupilumabHerpes labialisNRS scoresAdult patientsClinical findingsDupilumabTreatment optionsEffective therapyTralokinumabDisease durationJoint pain
2023
Lebrikizumab Provides Rapid Response in EASI Components and Itch in Moderate-to-Severe Atopic Dermatitis
Simpson E, Yosipovitch G, Eyerich K, Staumont-Sallé D, Shahriari M, Gallo G, Wolf E, Pierce E, Liu C, Zhong J, Agell H, De Bruin-Weller M. Lebrikizumab Provides Rapid Response in EASI Components and Itch in Moderate-to-Severe Atopic Dermatitis. SKIN The Journal Of Cutaneous Medicine 2023, 7: s279. DOI: 10.25251/skin.7.supp.279.Peer-Reviewed Original Research